US and EU accept vandetanib filing for advanced medullary thyroid cancer
This article was originally published in Scrip
Executive Summary
The US and European regulatory authorities have accepted submissions for review of AstraZeneca's drug candidate vandetanib, an oral multi-targeted kinase inhibitor, in the treatment of patients with advanced medullary thyroid cancer (MTC).